The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresect

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07257653 by Zhejiang University, with a registry enrolment figure of 70 participants, started 2025-10-21 and due to reach its primary completion in 2026-12-31. Interventions recorded: Cetuximab β；Fruquintinib；; Cetuximab β；Fruquintinib；anti-PD1 antibody；; Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody. Conditions listed: Colorectal Neoplasms; RAS; BRAF; Cetuximabβ; Fruquintinib. Primary outcome: PFS. Colorectal eligibility wording from the registry: "For patients aged 80-85, comprehensive functional assessments must be completed, and they may be enrolled if the investigator deems them tolerable, with an expected survival of over 3 months; 3) Histopathologically and/or cytologically confirmed, unresectable metastatic colorectal adenocarcinoma con". Sites: China. No results are recorded here; the registry entry is the source.